Insurers, Medicaid’s ‘proof of progress’ and pricing require more guidance from policymakers

Posted on

The FDA does not know or consider pricing when it grants approval of new drugs, causing problems for insurers and Medicaid about its coverage.

from Healthcarecare Finance News Feed http://www.healthcarefinancenews.com/news/insurers-medicaids-proof-progress-and-pricing-may-require-more-guidance-fda

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s